Bruker (FRA:BKD) Total Equity: €2,165 Mil (As of Mar. 2026)


FRA:BKD Bruker Corp FRA:BKD
86 GF Score
Price €54.74
GF Value €55.69
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Bruker Total Equity?

Bruker FRA:BKD +3.65% 86 Total Equity is €2,165 Mil as of Mar. 2026. GuruFocus rates FRA:BKD with a GF Score™ of 86/100 and a GF Value™ of €55.69 (Fairly Valued). The stock has 10 warning signs investors should review.

Bruker's total equity for the quarter that ended in Mar. 2026 was €2,165 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bruker Total Equity Historical Data

* Premium members only.

The historical data trend for Bruker's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bruker Total Equity Chart

Bruker Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 960.05 1,068.42 1,296.00 1,733.52 2,143.80

Bruker Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,712.36 1,618.52 2,123.53 2,143.80 2,164.92
FRA:BKD
86GF Score
Bruker Corp FRA:BKD
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bruker Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bruker's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=5330.156-3186.359
=2,144

Bruker's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=5303.055-3138.133
=2,165

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €2,165 Mil mean?
Bruker (FRA:BKD) has a Total Equity of €2,165 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Bruker and its competitors.
Is Bruker's Total Equity too high?
Bruker's current Total Equity is €2,165 Mil. Overall, Bruker has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bruker's Total Equity compare to GKOS and BIO?
Bruker's Total Equity of €2,165 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Bruker and its competitors. Bruker's current Total Equity is €2,165 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bruker stock overvalued right now?
Based on GuruFocus' analysis, Bruker (FRA:BKD) is currently considered Fairly Valued. The stock's GF Value™ is €55.69, compared to a current price of €54.74 — trading 1.7% below its estimated fair value. The current Total Equity is €2,165 Mil. Bruker's overall GF Score™ is 86/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Bruker (FRA:BKD), the current Total Equity is €2,165 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bruker (FRA:BKD) Overvalued in 2026?

Based on GuruFocus' analysis, Bruker stock appears to be undervalued. The current stock price of €54.74 is trading 1.7% below its estimated GF Value™ of €55.69. GuruFocus considers Bruker to be Fairly Valued.

Key valuation signals for FRA:BKD:

  • Total Equity: €2,165 Mil
  • GF Value™: €55.69 vs. price of €54.74 (1.7% below fair value)
  • GF Score™: 86/100 with 10 warning signs

No single metric tells the full story. See the FRA:BKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bruker Business Description

Address 40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
86GF Score

Get the complete analysis for FRA:BKD

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€54.74
Price
€55.69
GF Value